Top 10 Global Pharma Company Dramatically Improves Site Payments In Drive To Become Sponsor Of Choice

The demand for clinical trial participants continues to accelerate in number and specificity, and research sites remain the most important channel for patient recruitment. With sites having a finite capacity to run studies, pharmaceutical companies large and small need to develop and maintain a reputation for being a sponsor of choice – one that makes it easy for sites to be successful and focused on patient care – so that their study requests are not passed over. Losing high performing sites could lead to trial delays and millions of dollars in lost sales.

One top 10 pharmaceutical company initiated a focused effort to raise their favorability with clinical research sites, with the goal of becoming the #1 sponsor of choice. They surveyed sites with which they conducted clinical studies and found that cash flow issues, including poor payment cycle times, transparency, and traceability, were the most mentioned complaints. The sponsor realized that they needed to address the investigator payment process as quickly as possible to improve site satisfaction.

After a thorough analysis of potential process improvements and payment products, the pharmaceutical company selected IQVIA Site Payments Solution. It was the only offering found to have the scalability and flexibility needed to support the broad and diverse requirements of this global enterprise and its diverse network of clinical research sites.